In this episode Dr David Liew and Dr Tina Racunica discuss what you need to know about considering biologics in special populations particularly in patients with cancer, the new JAK inhibitors and where they fit in to treatment regimens, when to switch agents and how to balance clinical trial data among agents to make treatment decisions

David Liew is a rheumatologist and clinical pharmacologist at Austin Health in Melbourne, and has an active interest in the quality use of medicines in rheumatology.

Dr Tina Racunica is a rheumatologist and pharmacist. She is the director of her group private rheumatology practice in Melbourne.